Prediction of sustained virologic response based on week 4 and week 12 response in hepatitis C virus genotype 1 patients treated with peginterferon and ribavirin: Assessment in a favorable IL28B allele-prevalent area

Intervirology

Volumn 56, Issue 3, 2013, Pages 178-183

  Chung, Hyun Jung ^a   Lee, Jin Woo ^b   Kim, Young Soo ^b   Lee, Jung Il ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Inha University School of Medicine   (South Korea)

Author keywords

Chronic hepatitis C; Genotype 1; Negative predictive value; Peginterferon; Positive predictive value; Ribavirin; Sustained virologic response; Treatment na ve; Virologic response

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ALLELE; ANTIVIRAL THERAPY; ARTICLE; COMPLETE EARLY VIROLOGIC RESPONSE; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE; ANEMIA; DEPRESSION; DIABETES MELLITUS; DRUG WITHDRAWAL; GENE; HEPATITIS C VIRUS GENOTYPE 1; IL28B GENE; NEUTROPENIA; PATIENT COMPLIANCE; RAPID VIROLOGIC RESPONSE; RECURRENCE RISK; TREATMENT DURATION; TREATMENT OUTCOME; WEAKNESS;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; NUCLEOPOLYHEDROVIRUS;

EID: 84878016162     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000345539     Document Type: Article

References (19)

1. Manns MP, McHutchison JG, Gordon SC, Rustigi VK, Shiffman M, Reindollar R, Goddman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-965.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
3. Poordad F, McCone J Jr, Bacon BR, Bruno S, Mann MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 investigators: Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
4. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Ada N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team: Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
5. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB: An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
6. Camma C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, Cicchetti A, Colombo GL, Di Marco V, Gasbarrini A, Craxi A: Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012; 56: 850-860.
7. Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster FR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF: UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2012; 35: 647-662.
8. Missiha S, Heathcote J, Arenovich T, Khan K, Canadian Pegasys Expanded Access Group: Impact of Asian face on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007; 102: 2181-2188.
9. Lee S, Kim IH, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG, Lee CS, Choi CS, Cho EY, Kim HC: Efficacy and tolerability of pegylated interferon- α 2a plus riabvirin versus pegylated interferon- α 2b plus ribavirin in treatment-naïve chronic hepatitis C patients. Intervirology 2010; 53: 146-153.
10. Park SH, Park CK, Lee JW, Kim YS, Jeong SH, Kim YS, Kim JH, Hwang SG, Rim KS, Yim HJ, Cheong JY, Cho SW, Lee JS, Park YM, Jan JW, Lee CK, Shon JH, Yang JM, Ju YS: Efficacy of tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: A multicenter, retrospective observational study. Gut Liver 2012; 6: 98-106.
11. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-802.
12. Lyoo KS, Song MJ, Hur W, Choi JE, Hong SW, Kim CW, Bae SH, Choi JY, Choi SW, Shin EC, Yoon SK: Polymorphism near the IL28B gene in Korea hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. J Clin Virol 2011; 52: 363-366.
13. Martinot-Peignoux M, Maylin S, Moucari R, Ripault MP, Boyer N, Cardoso AC, Giuily N, Castelnau C, Pouteau M, Stern C, Auperin A, Bedossa P, Asselah T, Marcellin P: Viologic response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. Antivir Ther 2009; 14: 501-511.
14. Marcellin P, Cheinquer H, Curescu M, Dusheiko GM, Ferenci P, Horban A, Jensen D, Lengyel G, Mangia A, Ouzan D, Puoti M, Rodriguez-Torres M, Shiffman ML, Schmitz M, Tatsch F, Rizzetto M: High SVR rates in RVR patients in the larger real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012, DOI: 10.1002/hep.25892.
15. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL: Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial. Hepatology 2008; 47: 1884-1893.
16. Huang CF, Yang JF, Huang JF, Dai CY, Chiu CF, Hou NJ, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL, Yu ML: Early identification of achieving a sustained virologic response in chronic hepatitis C patients without a rapid virologic response. J Gastoenterol Hepatol 2010; 25: 758-765.
17. Deltenre P, Louvet A, Lemoine M, Mourad A, Fartoux L, Moreno C, Henrion J, Mathurin P, Serfaty L: Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: A meta-analysis. J Hepatol 2011; 55: 1187-1194.
18. Brandman D, Bacchetti P, Ayala CE, Maher JJ, Khalili M: Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin actin. Diabetes Care 2012; 35: 1090-1094.
19. Ogawa E, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Taniai H, Okada K, Kainuma M, Hayashi J: Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. J Hepatol 2012, DOI: 10.1016/j.jhep.2012.04.027.